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The etiology of intraventricular hemorrhage (IVH) in extremely low birth weight preterm
infants is multifactorial with circulatory instability and hemostasis being preeminent. This
study sought to determine if the germinal matrix layer remained intact when platelets were
above 200×109/L, a near normal level, and fell below that when IVH occurred. This was a
retrospective study of platelets and head ultrasounds (HUS) in infants 23–28 weeks ges-
tation. Analyses were descriptive, one way analysis of variance, Pearson Chi-square tests,
and t -tests. Platelet counts and HUS were linked in 114 infants during the first 3 days when
90% of IVHs occur. Mean platelet levels were >200×109/L in 68% of infant 23–24 weeks
gestation and 78% of those 25–26 weeks when there were no IVHs.These findings, if con-
firmed, suggest that improving hemostasis in high risk preterm infants by keeping platelet
levels >200×109/L may maintain the integrity of the germinal matrix layer and prevent
IVHs.
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INTRODUCTION
The etiology of intraventricular hemorrhage (IVH) is multifacto-
rial with prematurity, circulatory instability, and hemostasis being
preeminent (1, 2). The presence of germinal matrix and its fragile
vessels in the ganglion eminence makes the immature brain excep-
tionally vulnerable to hemorrhage, especially IVH (3). Efforts to
prevent IVH have not been entirely successful in previous stud-
ies. Theoretically, IVH could be prevented by limiting germinal
matrix layer hemorrhages (GMH) from enlarging and rupturing
into the cerebral ventricles (Figure 1). Studies have suggested that
extremely low birth weight (ELBW) infants may not be able to
accomplish this because of their innately limited hemostatic capac-
ity (4–6). One facet of their coagulation system that is not limited,
however, is the concentration of circulating platelets. Accepted
mean and median platelet levels in ELBW infants at birth are
greater than 200× 109/L (7–11).
The role of platelets in the etiology of GMH and IVH has been
questioned. Do lower platelets cause GMH-IVH or vice versa? In
the absence of specific clinical conditions known to lower platelets,
we postulated that platelet concentrations decrease as platelets are
consumed when GMH rupture into the cerebral ventricles. This
project was undertaken to study whether platelet concentrations
remaining at or above 200× 109/L during the first 3 days follow-
ing birth differentiate isolated germinal matrix layer hemorrhages
from those that enlarge and rupture into the cerebral ventricles.
If platelet levels at or greater than 200× 109/L distinguishes the
infant without an IVH from one with, theoretically IVH could be
prevented in high risk infants by keeping platelet concentrations
higher than is currently practiced.
Waiting for platelets to fall to levels defining neonatal thrombo-
cytopenia (<150× 109/L) before instituting platelet transfusions,
as currently practiced, has not proven beneficial in preventing IVH
in ELBW infants.
STUDY DESIGN AND METHODS
A retrospective review of the electronic medical records
(NeoDataR) of all preterm infants with gestational ages between 23
and 28 weeks was approved by our hospital’s Institutional Review
Board. The records of 241 infants admitted to our Newborn Inten-
sive Care Unit from January 1, 2006 through December 31, 2009,
were reviewed. Parental consent was not required.
Platelet counts were performed on a Beckman Coulter Counter
LH 750 or LH 500. The source of blood for the platelet counts could
not be determined. Head ultrasounds (HUS) were performed on
an Acuson Sequoia 512 ultrasound machine.
In order to achieve the study goal of determining whether
higher platelet concentrations differentiated ELBW infants with
no IVH from those with an IVH, we separated the five grades of
IVH into groups defining events confined to the germinal matrix
from those involving the cerebral ventricles. GMH and IVH were
graded using the system of Papile et al. (12) HUS with no GMH
were graded 0. The head ultrasound findings were separated into
three groups according to whether the germinal matrix was not
ruptured (grades 0–I) or had ruptured into an IVH (grades II–
III) or into the parenchyma (grade IV). For the analysis the three
groups of head ultrasound findings were analyzed according to
platelet counts above and below 200× 109/L.
Stata version 10 was used for the analyses, which consisted
of descriptive statistics, one way analysis of variance (ANOVA),
Pearson Chi-square tests, independent samples t -tests, and paired
t -tests (13). A p-value <0.05 was judged to be significant.
The investigator was not involved in the day to day management
of any of the study infants.
RESULTS
We focused on clinical data available during the first 3 days since
90% of IVH occur during that time (1). There were no infants
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FIGURE 1 | Unruptured germinal matrix hematoma. Photograph
courtesy of Kevin Bove, and A. James Mc Adams (deceased), Department
of Pathology, Cincinnati Children’s Medical Center.
with alloimmune thrombocytopenia or platelet trapping tumors.
Vitamin K administration is routine in our nurseries, but it was
documented in only 80% of the medical records. The presence of
central catheters was not documented. All but one infant received
Ampicillin, which is reported to affect bleeding times (14).
Two hundred and forty one infants met the initial criteria for
admission to the study. Twenty-two infants were excluded because
they were transferred to the NICU after day 3, or they died within
the first 2 days, or had only one platelet count in the first 3 days.
Sixty-nine percent of the infants were Caucasian, 24% Hispanics,
1% blacks, and 7% a mix of Asian and other ethnicities. Forty
additional infants were not included in the analysis because their
mothers had pregnancy-associated hypertension (PIH), which is
known to lower platelet numbers.
A definitive IVH grade was established by day 3 in 125 (70%) of
the remaining 179 infants. For the final analyses we linked platelet
levels that were performed on the same day or on the prior day, if
no same day measurement was recorded, with the definitive HUS
diagnosis. One hundred and fourteen (91%) of the 125 infants met
these criteria. None received a platelet transfusion. The clinical
characteristics of the 114 infants are shown in Table 1.
When the 114 infants were segmented by gestational age and
IVH grades, 68.4% of the infants between 23 and 24 weeks ges-
tation and 77.5% of the infants between 25 and 26 weeks with
IVH grades 0–I had mean platelet levels >200× 109/L. Only 16.7
and 27.3% of the infants in the same age groups had platelets
>200× 109/L with IVH grades II–III (p= 0.045 and 0.003, respec-
tively). Platelet levels and IVH grades were not significantly
associated in infants 27–28 weeks (p= 0.393).
Figure 2 shows mean platelet levels in infants 26 weeks gestation
or less grouped according to their HUS diagnosis. Mean platelet
levels were initially above or at 200× 109/L during the first 2 days
in infants with all grades of IVH but by day 3 the mean level fell to
between 150 and 175× 109/L when IVH grades II–IV were present
(p< 0.001). Median platelet values were also significantly lower in
infants with IVH grades II–IV compared to those with grade 0–I







Birth weight (g) 845.4 (197) 875.7 (248) 0.48
Gestational age (weeks) 25.7 (1.5) 25.8 (1.4) 0.49
Male (%) 62.0 46.9 0.11
Apgar score <7 (%) 61.2 39.7 0.02
Small for gestation (%) 4.0 1.6 0.42
Multiple births (%) 32.0 26.6 0.53
Maternal hypertension (%) 6.0 3.1 0.46
Antenatal corticosteroids (%) 74.0 82.8 0.25
Cesarean section (%) 46.0 39.1 0.46
Severe RDS (%) 100 98.4 0.38
Pneumothorax (%) 4.0 3.1 0.80
Chorioamnionitis (%) 41.7 62.9 0.03
Any bruising (%) 48.0 34.4 0.14
Death (%) 29.8 15.9 0.08
Values represent mean (SD) or percentages. RDS is respiratory distress syn-
drome.
FIGURE 2 | Platelet levels (mean±2SE) in 86 infants 26weeks
gestation or less with IVH grades 0–I and II–IV.
(p≤ 0.001). Figure 2 also shows that the range of platelet values
were never below 200× 109/L in infants with all grades of IVH on
day 1, but by day 3 the lowest platelet values (<150× 109/L) were
present in infants with IVH grades II–IV.
Coagulation studies were performed on only two infants. One
infant with a tracheal culture positive for Group B streptococcus
had a slightly prolonged prothrombin time (21 s), a normal par-
tial thromboplastin time (108 s), and a normal fibrinogen level
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(299 mg/dL) on day 1. His platelets fell from 221× 109/L on day 1
to 189× 109/L when a grade II IVH increased to a grade IV on day
2 to 3. The second infant was not septic and had a grade I IVH on
day 2 that progressed to a grade III by day 6. Coagulation studies
on day 5 showed a normal prothrombin time (12 s), partial pro-
thrombin time (44 s), and fibrinogen (261 mg/dL). His hematocrit
fell from 40 to 27% and his platelets fell from 219× 109/L on day
1 to 103× 109/L on day 3.
Neonatal hypotension, defined as a mean blood pressure lower
than that expected for gestational age, was associated with lower
platelet levels and higher grades of IVH by day 3 (p< 0.01). Apgar
scores <7 and chorioamnionitis also significantly associated with
lower platelet counts and IVH (Table 1). Neonatal sepsis was not
related to IVH.
DISCUSSION
In order to reduce or prevent IVH, special attention must focus on
maintaining the integrity of the germinal matrix layer. Past stud-
ies of IVH have not separated germinal matrix events from other
grades of IVH, as was done in this study. Most investigators use a
level of 150× 109/L or less as the benchmark for linking platelets
with IVH. The results of the current study show that on days 1
and 2 this level is low. By day 3 we observed continued lower-
ing of the platelet concentration suggesting that intraventricular
bleeding has occurred and platelets are being consumed. Conceiv-
ably, micro-hemorrhages in the germinal matrix layer could be
prevented from progressing into IVH by transfusing platelets in
high risk infants soon after birth and maintaining the level above
200× 109/L during the first 3 days.
In this study the germinal matrix layer of 68–78% of the infants
23–26 weeks gestation remained intact when mean platelet levels
were at or above 200× 109/L during the first 3 days. By compar-
ison infants with IVH grades II–III and IV had platelets below
that level. This finding suggests that platelet levels at or above of
200× 109/L define the dynamic hemorrhagic events more crit-
ically in the immature brain than levels below 150× 109/L, the
current definition of neonatal thrombocytopenia. Further, wait-
ing for platelet levels to fall below 50× 109/L to meet the current
guideline for platelet transfusions in preterm infants may be too
late to protect the germinal matrix layer and prevent IVH (15–18).
Platelet changes are reported to occur on day 2 in infants with
IVH (19, 20). We also found that platelets fell more rapidly on
days 2–3 when an IVH grade II or higher was present. These three
studies stress the importance of following platelets, hematocrit,
and coagulation values closely during the first 3 days in ELBW
infants that are at high risk for developing IVH.
The present study did not answer whether lower platelet levels
precede or are the consequence of IVH. Exposure to Ampicillin
and other conditions that have been associated with bleeding
and the etiology of IVH were addressed. Overall, in the absence
of other identified platelet consuming diseases, it seems reason-
able to suggest that in our study platelets were consumed more
rapidly once bleeding extended into the cerebral ventricles. Others
have reported that IVH occurs in association with a consumptive
coagulopathy and increased platelet destruction (21, 22).
Extremely low birth weight infants are at risk for hemorrhaging
because their platelets are hypoactive and bleeding times are long,
especially on day 1 (5, 6, 23, 24). Bleeding times, although difficult
to measure, reportedly improve with transfusions of adult platelets
(25). In another retrospective investigation platelet mass was stud-
ied to determine its relationship to IVH, since decreased platelet
mass is known to increase bleeding times (26). When platelet mass,
the product of mean platelet volume times platelet concentration,
fell to <10th percentile (1144 fl nL−1) on day 2, which was day 3
in our study, severe grades of IVH and increased mortality were
present. Unlike our study, the data in the referenced study were not
linked to those at highest risk for IVH, specifically infants 26 weeks
or less. Including larger and more mature preterm infants in stud-
ies of IVH dilutes the importance of findings related specifically to
the highly vulnerable extremely preterm infant. The role of platelet
mass in differentiating static GMH from those progressing to IVH
and the use of platelet mass as an indicator for platelet transfusion
requires further study, especially in infants <26 weeks gestation.
Andrew et al. first reported that thrombocytopenia, defined as
a platelet level<150× 109/L, increased the risk of IVH (27). They
then conducted the only prospective randomized controlled trial
of platelet transfusions in an attempt to prevent IVH (25). Trans-
fusions of adult platelets were administered when platelet levels
fell below 150× 109/L. Infants were transfused at a mean age of
1.92 days, about the same time that platelet levels were falling in
our study and in those of von Lindern et al. and Piotrowski et al.
(19, 20). Following transfusions, platelet levels rose and remained
above or near 200× 109/L. After re-grouping the Andrew’s data, it
appears that the percent of transfused infants with IVH grades 0–I
remained about the same on both initial and final HUS, so they
may have prevented some GMHs from progressing to IVH. Bleed-
ing times shortened in transfused infants but little was achieved in
reducing the number of infants with grade II and III hemorrhages
pre-and post transfusion (25). We believe that platelet transfusions
in their study were administered at a time when germinal matrix
rupture and intraventricular bleeding were underway. By then, it
was too late to prevent IVH.
In a recent publication, von Lindern and her colleagues showed
that the outcome of severe grades of IVH (grade III or IV) were
the same in preterm infants<32 weeks gestation whether a restric-
tive platelet transfusion protocol or a more liberal protocol was
used (28). Neither protocol required platelet transfusions at lev-
els of 200× 109/L. It appears that preventing IVH can only be
achieved by limiting GMHs from enlarging and rupturing. Wait-
ing for platelets to reach a lower level before considering platelet
transfusions may not be the method for preventing IVH.
Like most retrospective studies, this one also had major draw-
backs. First and foremost was the small study population which
was due mainly to HUS and platelet determinations not being
performed in all cases on the same day and within hours of each
other. Some records did not provide information about Vitamin
K administration even though it is a stated policy in our unit. In
addition, the use of central catheters was not always clearly stated.
Nevertheless, the findings provide a starting point for a prospec-
tive study in which HUS and platelet counts are temporally related
during the first 3 days. If the findings of such a study confirm those
in this study, a randomized prospectively designed protocol should
be considered. Knowing that increased mortality and morbidity
have been reported with four or more platelet transfusions, the
www.frontiersin.org September 2013 | Volume 1 | Article 22 | 3
Coen Prevent intraventricular hemorrhage
study design should employ early and a limited number of platelet
transfusions.
Finally, current guidelines recommend platelet transfusions for
sick newborns when platelet levels are <50× 109/L and there is
active bleeding. These guidelines may not apply to the manage-
ment of ELBW infants at high risk for IVH for several reasons.
First, there are no current scientifically based studies to support
the transfusion recommendations (16–18). Second, transfusing
preterm infants with adult platelets improves their bleeding times,
so why not try to stop a GMH before it segues into an IVH? Third,
one of the guidelines for transfusing platelets is evidence of active
bleeding. GMH-IVH can only be detected by ultrasound scans
and even then scans do not show active bleeding. The results of
the present study suggest that keeping platelets above 200× 109/L
rather than waiting for them to fall below 150× 109/L may provide
a clinical opportunity to prevent IVH.
CONCLUSION
This preliminary study showed that platelet concentrations at or
above 200× 109/L during the first 3 days defines the threshold
for differentiating events in the germinal matrix layer and IVH
in the immature brain. If the results are confirmed, future tri-
als may be designed to show whether IVH can be prevented by
improving the hemostatic capacity of the ELBW infant with early
and a limited number of platelet transfusions, administered either
prophylactically or as active treatment.
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